# Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis

> **NCT00832364** · PHASE4 · WITHDRAWN · sponsor: **Stiefel, a GSK Company**

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Acitretin (also called U0279)
- **DRUG:** Placebo
- **BIOLOGICAL:** Etanercept

## Key facts

- **NCT ID:** NCT00832364
- **Lead sponsor:** Stiefel, a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-10
- **Primary completion:** 2010-03
- **Final completion:** 2010-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision. No patients were enrolled
- **Last updated:** 2015-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00832364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00832364, "Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00832364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*